AEON Biopharma (AEON) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 13, 2025, at the company’s Irvine, CA headquarters, with shareholders encouraged to vote by proxy or in person.

• The company uses a notice-only option for proxy materials, providing online access and reducing paper use.

• As of the record date, there were 10,646,615 shares of Class A Common Stock outstanding, each entitled to one vote.

• The newly appointed CEO, Robert Bancroft, expressed commitment to the company’s mission and appreciation for shareholder support.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors (Jost Fischer and Eric Carter) for terms expiring at the 2028 annual meeting.

• Ratification of KPMG LLP as the independent registered public accounting firm for 2025 is on the agenda.

• No other matters are currently anticipated, but proxies allow for discretionary voting on any new business properly brought before the meeting.

• Shareholder proposals and director nominations for the 2026 meeting must comply with specific deadlines and requirements.

Board of directors and corporate governance

• The board consists of seven members divided into three classes, with staggered terms expiring in 2026, 2027, and 2028.

• Four directors are considered independent under NYSE American rules.

• The board has Audit, Compensation, and Nominating & Corporate Governance Committees, each with defined responsibilities and independent members.

• The roles of Chairperson and CEO are separated, with Jost Fischer serving as independent Chair and Robert Bancroft as CEO.

• The board met 16 times in 2024, with high attendance from all directors.